Complexities in defining remission in rheumatic diseases.
暂无分享,去创建一个
A Kavanaugh | T. Pincus | A. Kavanaugh | J. Smolen | D. Aletaha | T Pincus | D Aletaha | J Smolen | Theodore Pincus | T. Pincus | Arthur Kavanaugh
[1] Maarten Boers,et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. , 2004, Arthritis and rheumatism.
[2] L. Carmona,et al. Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. , 2004, The Journal of rheumatology.
[3] M. Oka,et al. Effect of pregnancy on the prognosis and serology of rheumatoid arthritis. , 1966, Acta rheumatologica Scandinavica.
[4] T. Pincus. The American College of Rheumatology (ACR) Core Data Set and derivative "patient only" indices to assess rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.
[5] H. Dodge,et al. A four year follow-up of suspected rheumatoid arthritis: the Tecumseh, Michigan, Community Health Study. , 1969, Arthritis and rheumatism.
[6] G G Koch,et al. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities , 2006, Annals of the rheumatic diseases.
[7] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[8] J Thumboo,et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. , 1999, Arthritis and rheumatism.
[9] A. Claudy,et al. Disease activity in systemic lupus erythematosus , 1979, Clinical and experimental dermatology.
[10] D. Mitchell,et al. Preliminary criteria for clinical remission in rheumatoid arthritis. , 1981, Arthritis and rheumatism.
[11] J. Braun,et al. Remission in ankylosing spondylitis. , 2006, Clinical and experimental rheumatology.
[12] Anajane G. Smith,et al. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. , 1993, The New England journal of medicine.
[13] P. Lipsky,et al. Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. , 2002, Arthritis and rheumatism.
[14] T. Pincus,et al. Quantitative measures and indices to assess rheumatoid arthritis in clinical trials and clinical care. , 2004, Rheumatic diseases clinics of North America.
[15] J. Kremer,et al. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. , 1987, The American journal of medicine.
[16] D. Gladman,et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. , 1997, Arthritis and rheumatism.
[17] F. Wolfe,et al. "No evidence of disease" in rheumatoid arthritis using methotrexate in combination with other drugs: a contemporary goal for rheumatology care? , 1997, Clinical and experimental rheumatology.
[18] T. Pincus,et al. Quantitative target values of predictors of mortality in rheumatoid arthritis as possible goals for therapeutic interventions: an alternative approach to remission or ACR20 responses? , 2001, The Journal of rheumatology.
[19] J. Smolen,et al. Remission of rheumatoid arthritis: should we care about definitions? , 2006, Clinical and experimental rheumatology.
[20] B. Dijkmans,et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis , 1996, The Lancet.
[21] David T Felson,et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. , 2005, The Journal of rheumatology.
[22] P. Tugwell,et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. , 1999, The Journal of rheumatology.
[23] F. Breedveld,et al. Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity , 2006, Arthritis research & therapy.
[24] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[25] P. V. van Riel,et al. The Disease Activity Score and the EULAR response criteria. , 2005, Clinical and experimental rheumatology.
[26] C. Allaart,et al. The Leiden Early Arthritis Clinic. , 2003, Clinical and experimental rheumatology.
[27] A. Silman,et al. Natural remission in inflammatory polyarthritis: issues of definition and prediction. , 1996, British journal of rheumatology.
[28] A. Ralston. Side effect , 2003 .
[29] T. Pincus,et al. Prognostic markers of activity and damage in rheumatoid arthritis: why clinical trials and inception cohort studies indicate more favourable outcomes than studies of patients with established disease. , 1995, British journal of rheumatology.
[30] N. Bellamy,et al. The WOMAC Knee and Hip Osteoarthritis Indices: development, validation, globalization and influence on the development of the AUSCAN Hand Osteoarthritis Indices. , 2005, Clinical and experimental rheumatology.
[31] J. Braun,et al. Assessment of ankylosing spondylitis. , 2005, Clinical and experimental rheumatology.
[32] Wei Chen,et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. , 2005, Arthritis and rheumatism.
[33] T. Pincus,et al. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures. , 2004, Clinical and experimental rheumatology.
[34] K. Eberhardt,et al. Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. , 1998, British journal of rheumatology.
[35] Andrea Messori,et al. New drugs for rheumatoid arthritis [6] (multiple letters) , 2004 .
[36] T. Pincus,et al. Mortality in the rheumatic diseases. , 1995, Arthritis care and research : the official journal of the Arthritis Health Professions Association.
[37] J. Kremer,et al. Combination Therapy with Multiple Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Preventive Strategy , 1999, Annals of Internal Medicine.
[38] V. Steen. Scleroderma renal crisis. , 2003, Rheumatic diseases clinics of North America.
[39] B. Svensson,et al. Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy. , 2000, Rheumatology.
[40] S. van der Linden,et al. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission , 2005, Annals of the rheumatic diseases.
[41] Tanja Stamm,et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. , 2005, Arthritis and rheumatism.
[42] H. Kautiainen,et al. Radiographic remission in seropositive rheumatoid arthritis. A 20-year follow-up study. , 2001, Clinical and experimental rheumatology.
[43] J. O'sullivan,et al. The prevalence of rheumatoid arthritis. Follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. , 1972, Annals of internal medicine.
[44] H. Mäkinen,et al. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? , 2005, Annals of the rheumatic diseases.
[45] H. Mäkinen,et al. Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. a 5-year followup study. , 2005, Journal of Rheumatology.
[46] Michael J. Green,et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. , 2003, Arthritis and rheumatism.
[47] T. Pincus,et al. Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. , 2005, Clinical and experimental rheumatology.
[48] P. Emery,et al. Early rheumatoid arthritis: time to aim for remission? , 1995, Annals of the rheumatic diseases.
[49] J. Smolen,et al. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.
[50] M. Prevoo,et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. , 1996, British journal of rheumatology.
[51] C. Bingham,et al. Remission in rheumatoid arthritis: wishful thinking or clinical reality? , 2005, Seminars in arthritis and rheumatism.
[52] R. Moots,et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.
[53] P. V. van Riel,et al. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. , 2004, Rheumatology.
[54] D. M. van der Heijde,et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results , 2005, Annals of the rheumatic diseases.
[55] P. Hannonen,et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. , 2005, Arthritis and rheumatism.
[56] Michael M Ward,et al. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. , 2006, Arthritis and rheumatism.
[57] T. Pincus,et al. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies. , 2004, Clinical and experimental rheumatology.
[58] P. Merkel,et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). , 2005, Arthritis and rheumatism.
[59] G. A. Bennett,et al. 1958 revision of diagnostic criteria for rheumatoid arthritis. , 1958, Arthritis and rheumatism.
[60] M. Petri,et al. Assessment of systemic lupus erythematosus. , 2005, Clinical and experimental rheumatology.
[61] Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. , 1970, JAMA.
[62] M. Dougados,et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study , 2004, Annals of the rheumatic diseases.
[63] James M Robins,et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.
[64] C. Goldsmith,et al. Interpretation and power of a pooled index. , 1993, The Journal of rheumatology.
[65] J. Ilonen,et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. , 2002, Arthritis and rheumatism.
[66] R N Maini,et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. , 2005, Arthritis and rheumatism.
[67] D. M. van der Heijde,et al. Radiographic progression in rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.
[68] A. Kavanaugh,et al. The assessment of disease activity and outcomes in psoriatic arthritis. , 2005, Clinical and experimental rheumatology.
[69] S. Cessie,et al. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study , 2005, Annals of the rheumatic diseases.
[70] R. Rau,et al. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. , 2000, Arthritis and rheumatism.
[71] M. Weinblatt,et al. Rheumatoid Arthritis: Treat Now, Not Later! , 1996, Annals of Internal Medicine.
[72] T. Pincus,et al. Placebo-controlled studies in rheumatoid arthritis: ethical issues , 1999, The Lancet.
[73] T. Wilt,et al. Effectiveness of statin therapy in adults with coronary heart disease. , 2004, Archives of internal medicine.
[74] H. Paulus. Defining remission in rheumatoid arthritis: what is it? Does it matter? , 2004, The Journal of rheumatology.